President Donald Trump recently proposed tariffs on pharmaceutical imports from countries like Ireland and India, both key hubs for drug manufacturing.
As a result, investors are bracing for potential disruptions to the global supply chain. The U.S. remains heavily reliant on imported drugs from low-cost manufacturing hubs like Ireland.
